Needham hosted an expert to discuss potential impact of trade tariffs and personnel changes on healthcare equities. Generic ...

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.'s compounded drug industry was hurting ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...